Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Olaf Stuve

Showing results (11-20 of 88) with videos related to

Pageof 9
Sort By:
Multiple Sclerosis and Related Disorders|January 25, 2022
To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in EnglandBastian Tugemann, Navid Manouchehri, Olaf Stuve
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2021
Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuationNatalia Gonzalez Caldito, Shirley O'Leary, Olaf Stuve
Neuropsychiatric Disease and Treatment|October 2, 2015
Intractable and highly active relapsing multiple sclerosis - role of alemtuzumabDivyanshu Dubey, Christopher A Cano, Olaf Stuve
Therapeutic Advances in Neurological Disorders|September 24, 2024
Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system databaseAfsaneh Shirani, Anne H Cross, Olaf Stuve
Therapeutic Advances in Neurological Disorders|April 3, 2024
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system databaseAfsaneh Shirani, Anne H Cross, Olaf Stuve
Neurologic Clinics|November 18, 2023
Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell DepletionAfsaneh Shirani, Olaf Stuve, Anne H Cross
Therapeutic Advances in Neurological Disorders|November 21, 2025
Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting SystemAfsaneh Shirani, Samuel A Goldlust, Olaf Stuve
Frontiers in Molecular Neuroscience|October 31, 2022
The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A reviewNil Saez-Calveras, Amy L Brewster, Olaf Stuve
Therapeutic Advances in Neurological Disorders|November 3, 2023
Perspective: Industry-patient relationships for the promotion of pharmaceutical agentsMeredith A Bryarly, Michael A Rubin, Olaf Stuve
Archives of Neurology|March 24, 2007
W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th centuryElliot M Frohman, Olaf Stuve, David H Miller
Pageof 9

Showing results (11-20 of 88) with videos related to

Sort By:
Pageof 9
Multiple Sclerosis and Related Disorders|January 25, 2022
To the editors: Impact of mass vaccination on SARS-CoV-2 infections among multiple sclerosis patients taking immunomodulatory disease-modifying therapies in EnglandBastian Tugemann, Navid Manouchehri, Olaf Stuve
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 23, 2021
Persistent severe lymphopenia 5 years after dimethyl fumarate discontinuationNatalia Gonzalez Caldito, Shirley O'Leary, Olaf Stuve
Neuropsychiatric Disease and Treatment|October 2, 2015
Intractable and highly active relapsing multiple sclerosis - role of alemtuzumabDivyanshu Dubey, Christopher A Cano, Olaf Stuve
Therapeutic Advances in Neurological Disorders|September 24, 2024
Author response to Comment on: Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system databaseAfsaneh Shirani, Anne H Cross, Olaf Stuve
Therapeutic Advances in Neurological Disorders|April 3, 2024
Exploring the association between weight loss-inducing medications and multiple sclerosis: insights from the FDA adverse event reporting system databaseAfsaneh Shirani, Anne H Cross, Olaf Stuve
Neurologic Clinics|November 18, 2023
Role of B Cells in Relapsing-Remitting and Progressive Multiple Sclerosis and Long-Term Effects of B Cell DepletionAfsaneh Shirani, Olaf Stuve, Anne H Cross
Therapeutic Advances in Neurological Disorders|November 21, 2025
Reporting patterns of multiple sclerosis with immune checkpoint inhibitors: analysis of the FDA Adverse Event Reporting SystemAfsaneh Shirani, Samuel A Goldlust, Olaf Stuve
Frontiers in Molecular Neuroscience|October 31, 2022
The validity of animal models to explore the pathogenic role of the complement system in multiple sclerosis: A reviewNil Saez-Calveras, Amy L Brewster, Olaf Stuve
Therapeutic Advances in Neurological Disorders|November 3, 2023
Perspective: Industry-patient relationships for the promotion of pharmaceutical agentsMeredith A Bryarly, Michael A Rubin, Olaf Stuve
Archives of Neurology|March 24, 2007
W. Ian McDonald, MB, ChB, PhD (1933-2006): the multiple sclerosis physician-scientist of the 20th centuryElliot M Frohman, Olaf Stuve, David H Miller
Pageof 9